Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart McPherson

Showing results (101-110 of 107) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 107 results.
Nature Communications|July 1, 2014
TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver diseaseYang-Lin Liu, Helen L Reeves, Alastair D Burt, et al.
Trials|September 27, 2022
ASEPTIC: primary antibiotic prophylaxis using co-trimoxazole to prevent SpontanEous bacterial PeritoniTIs in Cirrhosis-study protocol for an interventional randomised controlled trialDominic Crocombe, Norin Ahmed, Indran Balakrishnan, et al.
Wellcome Open Research|August 19, 2021
Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis CGraham S Cooke, Sarah Pett, Leanne McCabe, et al.
The Lancet. Gastroenterology & Hepatology|May 1, 2022
Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest GroupStuart McPherson, Matthew J Armstrong, Jeremy F Cobbold, et al.
Journal of Hepatology|August 30, 2024
Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis BMaria Buti, Jeong Heo, Yasuhito Tanaka, et al.
BMJ Open Gastroenterology|April 22, 2022
COVID-19 and liver cancer: lost patients and larger tumoursDaniel Geh, Robyn Watson, Gourab Sen, et al.
The Lancet. Gastroenterology & Hepatology|May 3, 2026
The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensusJeremy F Cobbold, Hamish Miller, Kate Hallsworth, et al.
Pageof 11

Showing results (101-110 of 107) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 107 results.
Nature Communications|July 1, 2014
TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver diseaseYang-Lin Liu, Helen L Reeves, Alastair D Burt, et al.
Trials|September 27, 2022
ASEPTIC: primary antibiotic prophylaxis using co-trimoxazole to prevent SpontanEous bacterial PeritoniTIs in Cirrhosis-study protocol for an interventional randomised controlled trialDominic Crocombe, Norin Ahmed, Indran Balakrishnan, et al.
Wellcome Open Research|August 19, 2021
Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis CGraham S Cooke, Sarah Pett, Leanne McCabe, et al.
The Lancet. Gastroenterology & Hepatology|May 1, 2022
Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest GroupStuart McPherson, Matthew J Armstrong, Jeremy F Cobbold, et al.
Journal of Hepatology|August 30, 2024
Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis BMaria Buti, Jeong Heo, Yasuhito Tanaka, et al.
BMJ Open Gastroenterology|April 22, 2022
COVID-19 and liver cancer: lost patients and larger tumoursDaniel Geh, Robyn Watson, Gourab Sen, et al.
The Lancet. Gastroenterology & Hepatology|May 3, 2026
The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensusJeremy F Cobbold, Hamish Miller, Kate Hallsworth, et al.
Pageof 11